Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 209

The DOI matches its Crossref record.

Blood Transfusion-Induced Immunomodulation

Landers, Dennis F., Hill, Gary E., Wong, K. C., Fox, Ira J.·1996·Anesthesia & Analgesia

Abstract

Blood transfusion therapy is associated with many risks, including major or minor blood transfusion reaction, non-A non-B hepatitis, hepatitis B, and HIV infection. Blood transfusion may result in immunologic changes (immunomodulation) that are beneficial in some patients but harmful in others. After reports of increased renal allograft survival in patients receiving pretransplant transfusion [1], Gantt [2] questioned whether transfusion might diminish or retard the immune response. Clinical studies have shown a beneficial effect of blood transfusion on graft survival [3,4], but an adverse effect on cancer recurrence [5-10] and postoperative infection [10-14]. Approximately two thirds of 11,000 transfusions [15,16] given perioperatively are administered by anesthesiologists [17], and 26% are given inappropriately [18,19]. This review will focus on the immunomodulatory effects of transfusion therapy. It will begin with a brief review of the immune system and then discuss 1) the effect of transfusion therapy on modulating the immune system, and 2) transfusion-induced immunomodulatory effects on vascularized graft survival, cancer recurrence, and postoperative infections. Immune System Overview The major function of the immune system is to recognize various pathogens and respond to them. Although the immune system evolved to inactivate pathogens, it is now known that it also protects the body against the development of tumors and the rejection of foreign tissue. The immune system consists of an afferent (recognition) limb and an efferent (response) limb. The afferent limb is involved with alerting the host against the entry of foreign pathogens or foreign alloantigens. The afferent (response) limb may respond by cellular and/or humoral immunity and by secretion of lymphokines that modulate the immune response [20]. Human Lymphoid System The lymphoid tissue is responsible for most of the body's immune response and contains about 1012 lymphocytes, which produce approximately 1020 antibody molecules [21]. The mature lymphocytes circulate to lymph nodes, spleen, or tonsils and remain in these secondary locations until they are activated by antigens and antigen-presenting cells [20]. T Lymphocytes T lymphocytes (T cells) are so named because they are matured by the thymus. T cells become activated by antigens and by antigen-presenting cells (APCs) and are characterized by an antigen-binding molecule or T-cell receptor (TCR) on their surface. TCRs react with antigens that have been processed and presented by major histocompatibility complex (MHC) molecules on the surface of macrophages or APCs. The TCR and the CD3 chain form a complex that functions as the primary antigen recognition site on the cell surface Figure 1. In addition to the TCR/CD3 molecules, numerous accessory surface molecules are present Figure 2. They include the CD8 and CD4 molecules, which bind to MHC class I and class II molecules on the APCs Figure 1[22].Figure 1: Interaction of a peptide-major histocompatibility complex (MHC) complex on a presenting cell with a receptor on a T cell. The presenting cell can be a macrophage using a class II MHC or any tissue cell using a class I MHC. The T cells can be helper T lymphocytes carrying CD4 or cytotoxic T lymphocytes carrying CD8. The class I MHC binds CD8; class II binds CD4. The T-cell receptor not only has CD8 or CD4 molecules as components of its interaction system, it also has four different proteins that make up the CD3 complex; their role is uncertain. Also, bound to the CD4 or CD8 proteins is the lck protein tyrosine kinase, which can phosphorylate a CD3 component on tyrosine in response to an interaction of the T-cell receptor with MHC-peptide complex. The CD3 and lck proteins are apparently part of the response system used by T cells after encounters with an MHC-peptide complex antigen. (From Darnell J, Lodish H, and Baltimore D. Molecular cell biology. 2nd ed. Copyright (c) 1990 by Scientific American Books, Inc., New York, NY. Used with permission of W. H. Freeman and Company.)Figure 2: Cell surface markers involved in T-cell activation and adhesion. Depicted are a number of T-cell surface molecules and their known ligands on the surface of antigen-presenting cells and/or the extracellular matrix. Many of these molecules are also known to deliver intracellular signals capable of interacting with the activation signal delivered through the T-cell receptor (TCR). HA, hyaluronic acid; FN, fibronectin; LN, laminin; Ag, antigen; PTP prime ase, protein tyrosine phosphatase; circles with dots represent phosphotyrosine residues; fyn (p59fyn) and lck (p56lck), protein tyrosine kinases. (Adapted with permission from Rothstein DM. The cellular immune response. In: Anderson KC, Ness PM, eds. Scientific basis of transfusion medicine--implications for clinical practice. Philadelphia: WB Saunders, 1994;124-46.)MHC I and MHC II antigens are cell surface glycoproteins that are responsible for alloreactivit

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00000539-199601000-00035

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 209

Metadata

Authors
Landers, D. F., Hill, G. E., Wong, K. C., & Fox, I. J.
Venue
Anesthesia & Analgesia
Published
1996-01
Volume
82
Issue
1
Pages
187-204
ISSN
0003-2999 (ISSN-L)
OpenAlex
W1976596342
Cited by
209
References
0
FWCI
6.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood Transfusion-Induced Immunomodulation. https://app.cochat.ai/papers/10.1097/00000539-199601000-00035
The paper
Landers, D. F., Hill, G. E., Wong, K. C., & Fox, I. J. (1996). Blood Transfusion-Induced Immunomodulation. Anesthesia & Analgesia. https://doi.org/10.1097/00000539-199601000-00035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.